Age (years) | | | | 0.616 |
80 (%) | 45 (56.3%) | 13 (54.2%) | 32 (57.1%) | |
61–80 (%) | 29 (36.3%) | 8 (33.3%) | 21 (37.5%) | |
41–60 (%) | 5 (6.3%) | 3 (12.5%) | 2 (3.6%) | |
<40 (%) | 1 (1.3%) | 0 (0.0%) | 1 (1.8%) | |
Gender | | | | 0.207 |
Female (%) | 52 (65.0%) | 18 (75.0%) | 34 (60.7%) | |
Male (%) | 28 (35.0%) | 6 (25.0%) | 22 (39.7%) | |
Race | | | | 0.582 |
Chinese (%) | 70 (87.5%) | 22 (91.7%) | 48 (85.7%) | |
Malay (%) | 8 (10.0%) | 2 (8.3%) | 6 (10.7%) | |
Indian (%) | 2 (2.5%) | 0 (0.0%) | 2 (3.6%) | |
Modified Barthel Index | | | | 0.340 |
<15 (moderate disability) (%) | 44 (55.0%) | 15 (62.5%) | 29 (51.8%) | |
>16 (independent) (%) | 26 (32.5%) | 6 (25.0%) | 20 (35.7%) | |
<10 (severe disability) (%) | 10 (12.5%) | 3 (12.5%) | 7 (12.5%) | |
Number of comorbidities | | | | 0.799 |
>5 (%) | 39 (48.8%) | 12 (50.0%) | 27 (48.2%) | |
2–5 (%) | 33 (41.3%) | 10 (41.7%) | 23 (41.1%) | |
<2 (%) | 8 (10.0%) | 2 (8.3%) | 6 (10.7%) | |
Abbreviated Mental Test | | | | 0.289 |
>6 (mild/no impairment) (%) | 48 (60.0%) | 13 (54.2%) | 35 (62.5%) | |
0–3 (severe impairment) (%) | 19 (23.8%) | 8 (33.3%) | 11 (19.6%) | |
4–6 (moderate impairment) (%) | 13 (16.3%) | 3 (12.5%) | 10 (17.9%) | |
Number of medications | | | | 0.731 |
5–10 (%) | 39 (48.8%) | 10 (41.7%) | 30 (53.6%) | |
>10 (%) | 29 (36.3%) | 9 (37.5%) | 19 (33.9%) | |
<5 (%) | 12 (15.0%) | 5 (20.8%) | 7 (12.5%) | |
Clinical frailty score | | | | 0.036 |
Very fit (%) | 1 (1.3%) | 0 (0.0%) | 1 (1.8%) | |
Well (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Managing well (%) | 2 (2.5%) | 0 (0.0%) | 2 (3.6%) | |
Vulnerable (%) | 9 (11.3%) | 0 (0.0%) | 9 (16.1%) | |
Mildly frail (%) | 20 (25.0%) | 6 (25.0%) | 14 (25.0%) | |
Moderately frail (%) | 8 (10.0%) | 2 (8.3%) | 6 (10.7%) | |
Severely frail (%) | 23 (28.8%) | 11 (45.8%) | 12 (21.4%) | |
Very severely frail (%) | 12 (15.0%) | 4 (16.7%) | 8 (14.3%) | |
Terminally ill (%) | 5 (6.3%) | 1 (4.2%) | 4 (7.1%) | |